Is Day One Biopharmaceuticals Inc (DAWN) overvalued? · rev $131.2M
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company listed on US.
This page asks whether Day One Biopharmaceuticals Inc (DAWN) looks expensive on cached numbers — not a short thesis.
Latest reported DAWN revenue for 2024-12-31 was $131.2M. Net income was -$95.5M. DAWN currently screens at market cap $656.8M.
DAWN currently screens at market cap $656.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DAWN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DAWN stock page for the full model, not this heading.
Not investment advice.